The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2019 | CART19-BE-01 trial: next-generation CAR T-cell therapy for CD19+ R/R leukemia and lymphoma
Valentín Ortiz-Maldonado, MD, of Hospital Clinic of Barcelona, Barcelona, Spain talks about the current status of the Phase I CART19-BE-01 pilot study (NCT03144583), which investigates the infusion of ARI-0002 cells (cesnicabtagene autoleucel)in patients with relapsed/refractory CD19+ hematological malignancies. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
